Quantcast

Nephrologists Indicate that Improvement in Renal Anemia Parameters is One of the Top Three Efficacy Attributes for a New Hyperphosphatemia Treatment

April 22, 2014

Improved Pill Burden Scored Highest in Terms of Delivery Attributes, According to Findings from Decision Resources Group

BURLINGTON, Mass., April 22, 2014 /PRNewswire/ — Decision Resources Group finds that reduction in mortality, reduction in serum phosphorus levels, followed by improvement in renal anemia parameters were selected by surveyed nephrologists as the top three most persuasive efficacy clinical trial end points when prescribing a new drug for the treatment of hyperphosphatemia. Additionally, in terms of relative importance among a list of delivery attributes, surveyed nephrologists in the United States and Europe scored improved pill burden the highest. This finding is likely due to the fact that hyperphosphatemia is a chronic condition that requires prolonged treatment.

http://photos.prnewswire.com/prnvar/20130103/MM36768LOGO

Other key findings from the DecisionBase report entitled Hyperphosphatemia: Payer and Physician Receptivity to Novel Treatments–Which Emerging Drugs Excite Them?:

    --  Attribute importance and unmet needs: Surveyed nephrologists in the U.S.
        believe that efficacy is the most important attribute, compared with
        safety and tolerability, and delivery. However, European nephrologists
        believe that efficacy is equally important to safety and tolerability.
        The report also notes that there is high unmet need for drug
        manufactures to develop hyperphosphatemia therapies without the risk for
        vascular calcification.
    --  U.S. payer perspectives: Seventy percent of surveyed U.S. payers
        indicate that a therapy offering the ability to reduce the incidence of
        individual non-serious GI side effects 30 percent greater than that of
        the benchmark therapy, sevelamer carbonate, would be placed on their
        organization's formulary even if priced at least 4 times higher than
        expected generic sevelamer pricing. Similar analysis is also provided in
        the report regarding payer receptivity to hyperphosphatemia therapies
        with: improved efficacy in reducing serum phosphorous levels; ability to
        reduce median erythropoiesis-stimulating agent (ESA) intake; and
        improved pill burden. Surveyed U.S. payers are particularly receptive to
        new hyperphosphatemia therapies in dialysis that offer ability to reduce
        median ESA intake.

Comments from Decision Resources Group Director Rob Dubman, MBA:

    --  "We thought that a reduction in median ESA intake would score higher in
        terms of an unmet need and attribute weight among surveyed nephrologists
        in the U.S. and Europe. However, the lower importance could stem from
        the fact that the concept of a phosphate binder reducing the need of an
        ESA intake is new to physicians, and many products are on the market
        today that treat renal anemia."
    --  "Traditionally, Sanofi's Renagel/Renvela has dominated the U.S. dialysis
        market in terms of physician preference. However, this report indicates
        that physician preference of two emerging therapies, Vifor Fresenius
        Medical Care Renal Pharma's Velphoro (approved by the FDA in November
        2013) and Keryx Biopharmaceutical's Zerenex (NDA submitted),
        respectively may actually receive higher physician preference compared
        with Renvela in a target product profile scenario analysis. However,
        these therapies will have a difficult time competing with generic
        sevelamer (Impax Laboratories launched an authorized generic of Renvela
        on April 16, 2014), as price was highly important to surveyed
        nephrologists."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort

781-993-2597

ccomfort@dresourcesgroup.com

Logo- http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group


Source: PR Newswire



comments powered by Disqus